Image Place holder

Samer Naffouje, MD

 
Specialty: Surgery
Program: Gastrointestinal Oncology

Overview

Dr. Samer Naffouje is a Clinical Instructor in the Department of Gastrointestinal Oncology. Dr. Naffouje earned his MD degree from the University of Damascus College of Medicine. He completed a General Surgery Residency at the University of Illinois Hospital and Health Sciences System in Chicago, where he also served as Chief Resident. He most recently completed a Complex General Surgical Oncology Fellowship at Moffitt Cancer Center. Dr. Naffouje’s clinical focus is GI minimally invasive surgery, particularly robotic surgery. His research interest centers on outcomes of upper GI, hepato-pancreato-biliary surgery, and colorectal resections for malignant indications. He is also interested in translational research on the precursors of pancreatic cancer. 


Education & Training

Fellowship:

  • University of Illinois - Surgical Oncology
  • Moffitt Cancer Center - Surgical Oncology
  • University of Illinois - Surgical Oncology
  • Moffitt Cancer Center - Surgical Oncology

Residency:

  • University of Illinois Hospital and Health Sciences System - Surgery
  • University of Illinois Hospital and Health Sciences System - Surgery

Medical School:

  • University of Damascus College of Medicine - MD
  • University of Damascus College of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Naffouje SA, Barker V, Lee MC, Hoover SJ, Laronga C. Surgical Management of Axilla of Triple-Negative Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database. Ann Surg Oncol. 2022 May.29(5):2985-2997. Pubmedid: 35006503.
  • Naffouje SA, Barker V, Lee MC, Hoover SJ, Laronga C. ASO Visual Abstract: Surgical Management of the Axilla of Triple-Negative Breast Cancer in the Z1071 Era-A Propensity-Score Matched Analysis of the National Cancer Database. Ann Surg Oncol. 2022 May.29(5):2998-2999. Pubmedid: 35076771.
  • Naffouje SA, Goto M, Coward LU, Gorman GS, Christov K, Wang J, Green A, Shilkaitis A, Das Gupta TK, Yamada T. Nontoxic Tumor-Targeting Optical Agents for Intraoperative Breast Tumor Imaging. J Med Chem. 2022 May.65(10):7371-7379. Pubmedid: 35544687.
  • Pointer DT, McDonald JA, Naffouje SA, Mehta R, Fleming JB, Fontaine JP, Lauwers GY, Frakes JM, Hoffe SE, Pimiento JM. The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer. J Surg Oncol. 2022 May. Pubmedid: 35578777.
  • Naffouje SA, Ali MA, Kamarajah SK, White B, Salti GI, Dahdaleh F. Assessment of Textbook Oncologic Outcomes Following Proctectomy for Rectal Cancer. J Gastrointest Surg. 2022 Jun.26(6):1286-1297. Pubmedid: 35441331.
  • Naffouje SA, Pointer DT, Satyadi MA, Hodul P, Anaya DA, Pimiento J, Malafa M, Kim DW, Fleming JB, Denbo JW. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Surg Endosc. 2022 Jul.36(7):4912-4922. Pubmedid: 34859301.
  • Naffouje S, Goto M, Ryoo I, Green A, Das Gupta TK, Yamada T. A Method of Tumor In Vivo Imaging with a New Peptide-Based Fluorescent Probe. Methods Mol Biol. 2022 Jan.2394:857-865. Pubmedid: 35094362. Pmcid: PMC8988467.
  • Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 Feb.26(2):376-386. Pubmedid: 34506031.
  • Naffouje SA, Lauwers G, Klapman J, Dam A, Pena L, Friedman M, Sanchez J, Dessureault S, Felder S. Malignant colon polyps: predicting lymph node metastasis following endoscopic excision. Int J Colorectal Dis. 2022 Feb.37(2):393-402. Pubmedid: 35001147.
  • Goto M, Ryoo I, Naffouje S, Mander S, Christov K, Wang J, Green A, Shilkaitis A, Das Gupta TK, Yamada T. Image-guided surgery with a new tumour-targeting probe improves the identification of positive margins. EBioMedicine. 2022 Feb.76:103850. Pubmedid: 35108666. Pmcid: PMC8814381.
  • Naffouje S, Sabesan A, Powers BD, Dessureault S, Sanchez J, Schell M, Imanirad I, Sahin I, Xie H, Felder S. Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. Clin Colorectal Cancer. 2021 Sep.20(3):e155-e164. Pubmedid: 33775560.
  • Naffouje SA, Sabesan A, Hoover SJ, Lee MC, Laronga C. ASO Visual Abstract: Surgical Management of the Axilla of HER2+ Breast Cancer in the Z1071 Era: A Propensity-Score Matched Analysis of the National Cancer Database. Ann Surg Oncol. 2021 Dec.28(Suppl 3):581-582. Pubmedid: 34363117.
  • Naffouje SA, Sabesan A, Hallanger-Johnson J, Kirtane K, Gonzalez RJ, Mullinax J. Adrenal biopsy, as a diagnostic method, is associated with decreased overall survival in patients with T1/T2 adrenocortical carcinoma: A propensity score-matched analysis. J Surg Oncol. 2021 Dec.124(8):1261-1271. Pubmedid: 34424540.
  • Allenson K, Turner K, Gonzalez BD, Gurd E, Zhu S, Misner N, Chin A, Adams M, Cooper L, Nguyen D, Naffouje S, Castillo DL, Kocab M, James B, Denbo J, Pimiento JM, Malafa M, Powers BD, Fleming JB, Anaya DA, Hodul PJ. Pilot trial of remote monitoring to prevent malnutrition after hepatopancreatobiliary surgery. BMC Nutr. 2021 Dec.7(1):82. Pubmedid: 34886909. Pmcid: PMC8656101.
  • Tang J, Wong G, Naffouje S, Felder S, Sanchez J, Dineen S, Powers BD, Dessureault S, Gurd E, Castillo D, Hodul P. A Novel Nomogram for Early Identification and Intervention in Colorectal Cancer Patients at Risk for Malnutrition. Am Surg. 2021 Dec. Pubmedid: 34920671.
  • Naffouje SA. ASO Author Reflections: Is Minimally Invasive Ivor-Lewis the Future of Esophagectomy?. Ann Surg Oncol. 2020 Dec.27(Suppl 3):719-720. Pubmedid: 32567034.
  • Shah H, Naffouje SA, Ejaz A. Providing Graduate Medical Education Orientation to Program Coordinators: A National Survey and Analysis. J Grad Med Educ. 2019 Oct.11(5):530-534. Pubmedid: 31636822. Pmcid: PMC6795314.
  • Naffouje SA, Salloum RH, Khalaf Z, Salti GI. Outcomes of Open Versus Minimally Invasive Ivor-Lewis Esophagectomy for Cancer: A Propensity-Score Matched Analysis of NSQIP Database. Ann Surg Oncol. 2019 Jul.26(7):2001-2010. Pubmedid: 30927192.
  • Naffouje SA, De La Cruz K, Berard D, Guy S, Salti GI. Knowledge, attitudes and practice of surgeons regarding nutritional support in CRS and HIPEC patients: Are we missing something?. Eur J Cancer Care (Engl). 2019 Jan.28(1):e12930. Pubmedid: 30298962.
  • Naffouje SA, Tulla KA, Khalaf Z, Salti GI. The impact of BMI extremes on disease-free survival and overall survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2019 Apr.10(2):194-202. Pubmedid: 31032085. Pmcid: PMC6465483.
  • Salti GI, Naffouje SA. Feasibility of hand-assisted laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy. Surg Endosc. 2019 01.33(1):52-57. Pubmedid: 29926165.
  • Naffouje SA, Tulla KA, Chorley R, Armstrong N, Salti GI. Acute kidney injury increases the rate of major morbidities in cytoreductive surgery and HIPEC. Ann Med Surg (Lond). 2018 Nov.35:163-168. Pubmedid: 30310679. Pmcid: PMC6178214.
  • Naffouje SA, Salti GI. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients: Complete Cytoreduction Is Feasible and Crucial for Improved Survival Despite High Carcinomatosis Index. Anticancer Res. 2018 Jan.38(1):441-448. Pubmedid: 29277807.
  • Naffouje SA, Tulla KA, Salti GI. A Simplified Peritoneal Sarcomatosis Score for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2018 Dec.9(6):1138-1143. Pubmedid: 30603133. Pmcid: PMC6286947.
  • Naffouje SA, Tulla KA, Salti GI. The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. Med Oncol. 2018 Apr.35(5):69. Pubmedid: 29651664.
  • Naffouje SA, Salti GI. Transient Exocrine Pancreatic Insufficiency: First Report of an Unrecognized Complication of Cytoreductive Surgery and HIPEC. Anticancer Res. 2018 Apr.38(4):2353-2358. Pubmedid: 29599360.
  • Naffouje SA, Salti GI. Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database. J Gastric Cancer. 2017 Dec.17(4):319-330. Pubmedid: 29302372. Pmcid: PMC5746653.
  • Naffouje SA, Tzvetanov I, Bui JT, Gaba R, Bernardo K, Jeon H. Obesity Increases the Risk of Primary Nonfunction and Early Access Loss, and Decreases Overall Patency in Patients Who Underwent Hemodialysis Reliable Outflow Device Placement. Ann Vasc Surg. 2016 Oct.36:236-243. Pubmedid: 27421202.
  • Naffouje SA, Anderson RR, Salti GI. A case report of Hepatoid Carcinoma of the Ovary with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy without systemic adjuvant therapy. Int J Surg Case Rep. 2016 Aug.27:83-86. Pubmedid: 27567979. Pmcid: PMC5007418.
  • Naffouje SA, O'Donoghue C, Salti GI. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system. J Surg Oncol. 2016 Apr.113(5):544-547. Pubmedid: 26750613.
  • Naffouje SA, Naffouje R, Chen J, Salti GI. Validation and Enhancement of the Clinicopathological Melanoma Nomogram via Incorporation of a Molecular Marker in the Primary Tumor. Anticancer Res. 2016 12.36(12):6603-6610. Pubmedid: 27919990.
  • Bhagwandin SB, Naffouje S, Salti G. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge. J Surg Oncol. 2015 Mar.111(3):324-327. Pubmedid: 25557653.
  • Naffouje S, Naffouje R, Bhagwandin S, Salti GI. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival. Melanoma Res. 2015 Dec.25(6):496-502. Pubmedid: 26317170.
  • Bhagwandin S, Naffouje S, Salti G. Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2015 Aug.22(8):2573-2577. Pubmedid: 25572680.
  • Myers EA, Feingold DL, Arnell TD, Njoh L, Cekic V, Jang JH, Naffouje S, Whelan RL. The rate for the use of hand-assisted laparoscopic methods is directly proportional to body mass index. Surg Endosc. 2014 Jan.28(1):108-115. Pubmedid: 23996331.
  • Jang JH, Kirchoff D, Holzman K, Park K, Grieco M, Cekic V, Naffouje S, Kluft J, Whelan RL. Laparoscopic-facilitated endoscopic submucosal dissection, mucosal resection, and partial circumferential ("wedge") colon wall resection for benign colorectal neoplasms that come to surgery. Surg Innov. 2013 Jun.20(3):234-240. Pubmedid: 22858573.
  • Shantha Kumara HM, Kirchoff D, Naffouje S, Grieco M, Herath SA, Dujovny N, Kalady MF, Hyman N, Njoh L, Whelan RL. Plasma from the second and third weeks after open colorectal resection for cancer stimulates in vitro endothelial cell growth, migration, and invasion. Surg Endosc. 2012 Mar.26(3):790-795. Pubmedid: 22083320.
  • Yan X, Gardner TR, Grieco M, Herath SA, Jang JH, Kirchoff D, Njoh L, Shantha Kumara HM, Naffouje S, Whelan RL. Perioperative polyphenon E- and siliphos-inhibited colorectal tumor growth and metastases without impairment of gastric or abdominal wound healing in mouse models. Surg Endosc. 2012 Jul.26(7):1856-1864. Pubmedid: 22258296.
  • Linkov G, Naffouje S, McGinty JJ. Ileocecal fold of Treves: a rare cause of small bowel obstruction. Am Surg. 2011 Feb.77(2):235-236. Pubmedid: 21337889.

Patient Comments
Overall Satisfaction
0

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments